Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Capricor Therapeutics (CAPR) over the last 15 years, with Dec 2024 value amounting to -$116.2 million.

  • Capricor Therapeutics' Cash from Investing Activities rose 695.70% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 5267.37%. This contributed to the annual value of -$116.2 million for FY2024, which is 2374.45% down from last year.
  • Per Capricor Therapeutics' latest filing, its Cash from Investing Activities stood at -$116.2 million for FY2024, which was down 2,374.45% from $5.1 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Cash from Investing Activities peaked at $5.4 million during FY2020, and registered a low of -$116.2 million during FY2024.
  • Over the past 3 years, Capricor Therapeutics' median Cash from Investing Activities value was -$35.1 million (recorded in 2022), while the average stood at -$48.7 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 281.18% in 2020, then plummeted by 2,831.78% in 2022.
  • Over the past 5 years, Capricor Therapeutics' Cash from Investing Activities (Yearly) stood at $5.4 million in 2020, then tumbled by 121.99% to -$1.2 million in 2021, then plummeted by 2,831.78% to -$35.1 million in 2022, then surged by 114.56% to $5.1 million in 2023, then plummeted by 2,374.45% to -$116.2 million in 2024.